G. Kontoghiorghes

J. Aaseth, T. Flaten, G. Kontoghiorghes, 2012, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients

G. Kontoghiorghes, 2011, Hemoglobin.

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

G. Kontoghiorghes, A. Kolnagou, M. Kleanthous, 2010, European journal of haematology.

A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients

G. Kontoghiorghes, 2009, Hemoglobin.

Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide

G. Kontoghiorghes, 2008, Hemoglobin.

Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients

G. Kontoghiorghes, 2022, International journal of molecular sciences.

Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines.

G. Kontoghiorghes, J. Blatt, S. Taylor, 1989, Cancer research.

Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1

A. Hoffbrand, G. Kontoghiorghes, B. Wonke, 1992, British journal of haematology.

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

A. Hoffbrand, G. Kontoghiorghes, L. Sheppard, 1987, British medical journal.

Oral iron chelation is here.

G. Kontoghiorghes, 1991, BMJ.

Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology

G. Kontoghiorghes, 2022, International journal of molecular sciences.

The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.

A. Hoffbrand, P. Dandona, G. Kontoghiorghes, 1988, The Biochemical journal.

Cytotoxic and DNA‐inhibitory effects of iron chelators on human leukaemic cell lines

A. Piga, A. Hoffbrand, G. Kontoghiorghes, 1986, Hematological oncology.

Cytotoxic effects of the lipophilic iron chelator omadine

A. Piga, A. Hoffbrand, G. Kontoghiorghes, 1986, FEBS letters.

Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine

G. Kontoghiorghes, N. Polyakov, O. Selyutina, 2022, International journal of molecular sciences.

Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte.

H. G. van Eijk, G. Kontoghiorghes, J. Koster, 1987, Free radical research communications.

Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2008, Hemoglobin.

Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

K. Kyriacou, Christos Kontos, G. Kontoghiorghes, 2008, Hemoglobin.

Decrease solubilisation of ferritin iron and Fresh iron(III) precipitate following repeated chelator treatments

G. Kontoghiorghes, 1987 .

Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor)

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2016, Haematologica.

Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity

D. Mikhailidis, P. Dandona, G. Kontoghiorghes, 1989, FEBS letters.

Interactions Of Hydroxycarbamide (Hydroxyurea) With Iron And Copper: Implications On Toxicity and Therapeutic Strategies

G. Kontoghiorghes, I. Pashalidis, A. Kolnagou, 2011, Hemoglobin.

Chelators Controlling Metal Metabolism and Toxicity Pathways: Applications in Cancer Prevention, Diagnosis and Treatment

G. Kontoghiorghes, A. Kolnagou, Aglaia Efstathiou, 2008, Hemoglobin.

Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES

A. Hoffbrand, A. Bartlett, G. Kontoghiorghes, 1990, British journal of haematology.

Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.

G. Kontoghiorghes, A. Kolnagou, Marios Kleanthous, 2022, Frontiers in bioscience.

The Role of Iron and Chelators on Infections in Iron Overload and Non Iron Loaded Conditions: Prospects for the Design of New Antimicrobial Therapies

G. Petrikkos, A. Skiada, G. Kontoghiorghes, 2010, Hemoglobin.

The effect of synthetic iron chelators on bacterial growth in human serum.

J. Brock, G. Kontoghiorghes, J. Liceaga, 1988, FEMS microbiology immunology.

Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones

G. Kontoghiorghes, L. Sheppard, 1987 .

Maintenance of Normal Range Body Iron Store Levels for up to 4.5 Years in Thalassemia Major Patients Using Deferiprone Monotherapy

G. Kontoghiorghes, A. Kolnagou, 2010, Hemoglobin.

Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

A. Swaak, G. Vreugdenhil, H. G. van Eijk, 1991, Clinical and experimental rheumatology.

1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD

A. Hoffbrand, G. Kontoghiorghes, L. Sheppard, 1987, The Lancet.

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

G. Kontoghiorghes, A. Kolnagou, K. Pattichis, 2004, Current medicinal chemistry.

The Proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies

G. Kontoghiorghes, 2013, Toxicology mechanisms and methods.

Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K‐562 and U‐937 cell lines induced by chelators and their iron complexes

K. Nilsson, G. Kontoghiorghes, K. Forsbeck, 1987, European journal of haematology.

Site specificity of iron removal from transferrin by α‐ketohydroxypyridine chelators

G. Kontoghiorghes, R. Evans, 1985 .

Structure/iron binding activity of 1-hydroxypyrid-2-one chelators intended for clinical use

G. Kontoghiorghes, 1987 .

Comparative iron binding studies of bis- and tris(3-hydroxy-2-methylpyrid-4-ones) and desferrioxamine

G. Kontoghiorghes, L. Sheppard, 1991 .

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

G. Kontoghiorghes, C. Kontoghiorghe, 2016, Drug design, development and therapy.

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone

G. Kontoghiorghes, N. Polyakov, O. Selyutina, 2021, Molecules.

How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?

G. Kontoghiorghes, 2020, Expert review of hematology.

Chelation protocols for the elimination and prevention of iron overload in thalassaemia.

G. Kontoghiorghes, A. Kolnagou, 2018, Frontiers in bioscience.

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia

G. Kontoghiorghes, C. Kontoghiorghe, Marios Kleanthous, 2020, Mediterranean journal of hematology and infectious diseases.

Antioxidant targeting by deferiprone in diseases related to oxidative damage.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2014, Frontiers in bioscience.

Risk/Benefit Assessment, Advantages Over Other Drugs and Targeting Methods in the Use of Deferiprone as a Pharmaceutical Antioxidant in Iron Loading and Non Iron Loading Conditions

G. Kontoghiorghes, Y. Michaelides, Anita Kolnagou, 2009, Hemoglobin.

Uses and Limitations of Serum Ferritin, Magnetic Resonance Imaging T2 and T2* in the Diagnosis of Iron Overload and in the Ferrikinetics of Normalization of the Iron Stores in Thalassemia Using the International Committee on Chelation Deferiprone/Deferoxamine Combination Protocol

E. Eracleous, G. Kontoghiorghes, C. Economides, 2009, Hemoglobin.

Advances in the Prevention and Treatment are Changing Thalassemia from a Fatal to a Chronic Disease. Experience from a Cyprus Model and its Use as a Paradigm for Future Applications

G. Kontoghiorghes, Anita Kolnagou, 2009, Hemoglobin.

Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox

G. Kontoghiorghes, 2008, Hemoglobin.

Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators

G. Kontoghiorghes, A. Kolnagou, 2006, Hemoglobin.

Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2*

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2006, Hemoglobin.

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

G. Kontoghiorghes, A. Kolnagou, C. Fessas, 2004, British journal of haematology.

Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

G. Kontoghiorghes, A. Kolnagou, K. Neocleous, 2003, Drug safety.

Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.

A. Hoffbrand, G. Kontoghiorghes, B. Wonke, 1992, Blood.

L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia major

A. Hoffbrand, A. Hirt, G. Kontoghiorghes, 1990, British journal of haematology.

Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*

G. Kontoghiorghes, A. Kolnagou, K. Natsiopoulos, 2013, Toxicology mechanisms and methods.

Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone

G. Kontoghiorghes, N. Polyakov, T. Kobzeva, 2019, JBIC Journal of Biological Inorganic Chemistry.

Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.

G. Kontoghiorghes, N. Polyakov, T. Kobzeva, 2015, Free radical biology & medicine.

Photoinduced transformation of iron chelator deferiprone: Possible implications in drug metabolism and toxicity

G. Kontoghiorghes, N. Polyakov, V. A. Timoshnikov, 2014 .

Prospects for introducing deferiprone as potent pharmaceutical antioxidant.

G. Kontoghiorghes, 2009, Frontiers in bioscience.

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.

G. Kontoghiorghes, 1996, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.

G. Kontoghiorghes, 1995, Toxicology letters.

New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.

G. Kontoghiorghes, 1995, The Analyst.

The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelators

G. Kontoghiorghes, 1986 .

In vitro screening of iron chelators using models of free radical damage.

J. Lunec, M. Jackson, G. Kontoghiorghes, 1986, Free radical research communications.

Oxidative effects of iron on erythrocytes.

C. Rice-Evans, A. Hoffbrand, G. Kontoghiorghes, 1985, Free radical research communications.

New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer

G. Kontoghiorghes, 2022, International journal of molecular sciences.

Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities

G. Kontoghiorghes, 2007, Expert opinion on drug safety.

The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2013, Toxicology mechanisms and methods.

CLINICAL TRIALS WITH ORAL IRON CHELATOR L1

A. Hoffbrand, G. Kontoghiorghes, 1989, The Lancet.

Long‐term trial with the oral iron chelator 1,2‐dimethy1‐3‐hydroxypyrid‐4‐one (L1) II. CLINICAL OBSERVATIONS

A. Hoffbrand, A. Bartlett, G. Kontoghiorghes, 1990, British journal of haematology.

Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone

P. Maher, G. Kontoghiorghes, 2015, Neurochemical Research.

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

E. Eracleous, G. Kontoghiorghes, A. Kolnagou, 2005, Current medicinal chemistry.

Design, Properties, and Effective Use of the Oral Chelator L1 and Other

G. Kontoghiorghes, 1990, Annals of the New York Academy of Sciences.

Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone

G. Kontoghiorghes, N. Polyakov, T. Kobzeva, 2020, International journal of molecular sciences.

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

G. Kontoghiorghes, A. Kolnagou, M. Hadjigavriel, 2000, Transfusion science.

Future Chelation Monotherapy and Combination Therapy Strategies in Thalassemia and Other Conditions. Comparison of Deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and Starch Deferoxamine Polymers

G. Kontoghiorghes, 2006, Hemoglobin.

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

G. Kontoghiorghes, A. Kolnagou, 2006, Haematologica.

Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2015, Molecules.

Iron chelating drugs

G. Kontoghiorghes, 1988, British medical journal.

Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone

G. Kontoghiorghes, N. Polyakov, T. Kobzeva, 2019, JBIC Journal of Biological Inorganic Chemistry.

New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications

G. Kontoghiorghes, A. Kolnagou, Theodora Demetriou, 2021, International journal of molecular sciences.

Advances on Chelation and Chelator Metal Complexes in Medicine

G. Kontoghiorghes, 2020, International journal of molecular sciences.

Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.

A. Hoffbrand, G. Kontoghiorghes, S. Chambers, 1987, The Biochemical journal.

Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.

G. Kontoghiorghes, 1987, Acta haematologica.

Selection of a new generation of orally active α‐ketohydroxypyridine iron chelators intended for use in the treatment of iron overload

G. Kontoghiorghes, L. Sheppard, J. Barr, 1993, American journal of hematology.

Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications

G. Kontoghiorghes, N. Polyakov, C. Kontoghiorghe, 2020, Medicines.

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

S. Shah, G. Kontoghiorghes, A. Aessopos, 2010, Expert opinion on drug safety.

Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2017, Drug Research.

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2014, World journal of methodology.

Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

G. Kontoghiorghes, A. Kolnagou, Marios Kleanthous, 2011, Hemoglobin.

The Proceedings Of The 19Th International Conference On Chelation Held In London, United Kingdom: Major Changes In Iron Chelation Therapy In The Last 25 Years Using Deferiprone (L1) Has Resulted In The Complete Treatment Of Iron Overload

G. Kontoghiorghes, 2011, Hemoglobin.

New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores

G. Kontoghiorghes, A. Kolnagou, 2010, British journal of haematology.

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

G. Kontoghiorghes, 2010, Expert opinion on drug safety.

Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption

G. Kontoghiorghes, George J Kontoghiorghes, Aspasia Spyrou, 2010, Hemoglobin.

Iron Mobilization From Transferrin And Non-Transferrin-Bound-Iron by Deferiprone. Implications in the Treatment of Thalassemia, Anemia of Chronic Disease, Cancer and Other Conditions

G. Kontoghiorghes, 2006, Hemoglobin.

Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one

G. Kontoghiorghes, L. Sheppard, J. Goddard, 1990, Clinical pharmacology and therapeutics.

Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators

G. Kontoghiorghes, 1986 .

Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids.

G. Kontoghiorghes, J. Goddard, 1990, Clinical chemistry.

Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications.

G. Kontoghiorghes, I. Pashalidis, 2000, Transfusion science.

Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases

G. Kontoghiorghes, C. Kontoghiorghe, 2020, Cells.

The aim of iron chelation therapy in thalassaemia

G. Kontoghiorghes, 2017, European journal of haematology.

Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.

A. Bartlett, G. Kontoghiorghes, L. Sheppard, 1995, Arzneimittel-Forschung.

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

G. Kontoghiorghes, A. Kolnagou, 2005, Current medicinal chemistry.

Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.

G. Kontoghiorghes, L. Sheppard, 1993, Arzneimittel-Forschung.

AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIAL

P. Veys, A. Hoffbrand, A. Bartlett, 1989, The Lancet.

The design of orally active iron chelators for the treatment of thalassaemia.

G. Kontoghiorghes, 1982 .

Advances in oral iron chelation in man.

G. Kontoghiorghes, 1992, International journal of hematology.

Chelators affecting iron absorption in mice.

G. Kontoghiorghes, 1990, Arzneimittel-Forschung.

Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches.

E. Weinberg, G. Kontoghiorghes, E D Weinberg, 1995, Blood reviews.

Effect of novel 1‐alkyl‐3‐hydroxy‐2‐methylpyrid‐4‐one chelators on uptake and release of iron from macrophages

J. Brock, G. Kontoghiorghes, J. Liceaga, 1990, American journal of hematology.

Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-one iron chelators

G. Kontoghiorghes, L. Sheppard, J. Barr, 1988 .

Structure/red blood cell permeability. Activity of iron(III) chelator complexes

G. Kontoghiorghes, 1988 .

2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation.

G. Kontoghiorghes, 1987, Biochimica et biophysica acta.

The effect of 2,4-dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice.

G. Kontoghiorghes, 1987, Clinica chimica acta; international journal of clinical chemistry.

Dose response studies using desferrioxamine and orally active chelators in a mouse model.

G. Kontoghiorghes, 2009, Scandinavian journal of haematology.

Mobilisation of plutonium and iron from transferrin and ferritin by hydroxypyridone chelators

G. Kontoghiorghes, David Taylor, 1986 .

EFFICACY AND SAFETY OF ORAL IRON CHELATOR L1 IN ANAEMIC RHEUMATOID ARTHRITIS PATIENTS

H. G. Eijk, A. Swaak, G. Vreugdenhil, 1989, The Lancet.

The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic.

G. Kontoghiorghes, C. Kontoghiorghe, S. Fetta, 2021, Frontiers in bioscience.

Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato’s Cave

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2021, International journal of molecular sciences.

Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases

G. Kontoghiorghes, 1993, Indian journal of pediatrics.

In vivo testing of oral iron chelators intended for clinical use.

G. Kontoghiorghes, 1991, Blood.

ASSESSMENT OF ORAL 1,2‐DIMETHYL–3‐HYDROXYPYRID–4–ONE (L1) IN DIFFERENT FERRIKINETIC MODELS IN ANIMALS AND HUMANS

G. Kontoghiorghes, 1991, British journal of haematology.

Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.

A. Hoffbrand, A. Bartlett, G. Kontoghiorghes, 1989, Progress in clinical and biological research.

New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.

G. Kontoghiorghes, L. Sheppard, S. Chambers, 1987, Arzneimittel-Forschung.

Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.

G. Kontoghiorghes, 1986, Molecular pharmacology.

NEW ORALLY ACTIVE IRON CHELATORS

G. Kontoghiorghes, 1985, The Lancet.

Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients

G. Kontoghiorghes, 2008 .

Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.

G. Kontoghiorghes, 2008, Expert opinion on drug safety.

Antimalarial properties of orally active iron chelators

J. Eaton, G. Kontoghiorghes, P. Hallaway, 1988 .

Antimalarial properties of orally active iron chelators.

J. Eaton, G. Kontoghiorghes, P. E. Hallaway, 1988, Blood.

Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium(VI)

G. Kontoghiorghes, I. Pashalidis, 1999 .

Orally active α‐ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits

A. Hoffbrand, G. Kontoghiorghes, 1986, British journal of haematology.

Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells

G. Kontoghiorghes, A. May, 2005, Biology of Metals.

Future of oral iron chelator deferiprone. (L1) ICOC committee.

M. Kersten, Y. Rahman, G. Vreugdenhil, 1993, Lancet.

Structure/Red Blood Cell Permeability. Activity of Iron(III) Chelator Complexes.

G. Kontoghiorghes, 1988 .

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2017, Mediterranean journal of hematology and infectious diseases.

Effects on Mycobacterium avium Replication in Normal Human Macrophages by Deferiprone (L1) and Other Iron Chelators

G. Kontoghiorghes, A. Kolnagou, M. May, 2002, Arzneimittelforschung.

Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig

J. Papadimitriou, G. Kontoghiorghes, V. Berdoukas, 1997, Biometals.

SAFETY OF ORAL IRON CHELATOR L1

G. Kontoghiorghes, L. Sheppard, J. Goddard, 1989, The Lancet.

Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

G. Kontoghiorghes, R. Baillod, J. Barr, 1994, Arzneimittel-Forschung.

Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects

G. Kontoghiorghes, 2023, International journal of molecular sciences.

Molecular Factors Affecting the Complex Formation between Deferiprone (L1) and Cu(II)

G. Kontoghiorghes, I. Pashalidis, 2001, Arzneimittelforschung.

The Effects of Bicarbonate and its Combination with Chelating Agents Used for the Removal of Depleted Uranium in Rats

Yuyuan Xie, A. Katoh, G. Kontoghiorghes, 2008, Hemoglobin.

New chelation therapies and emerging chelating drugs for the treatment of iron overload

G. Kontoghiorghes, George J Kontoghiorghes, 2006, Expert opinion on emerging drugs.

Radiation Protection by Deferiprone in Animal Models

A. Katoh, G. Kontoghiorghes, K. Anzai, 2006, Hemoglobin.

Misinformation about deferiprone (L1)

G. Kontoghiorghes, 1993, The Lancet.

Update of worldwide iron chelation therapy with L1 (deferiprone)

G. Kontoghiorghes, 1995 .

Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone

P. Maher, G. Kontoghiorghes, 2015, Neurochemical Research.

EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment

T. Born, G. Kontoghiorghes, C. Kontoghiorghe, 2013, Toxicology mechanisms and methods.

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases

G. Kontoghiorghes, 2023, Pharmaceuticals.

Editorial [Hot Topic: Regulatory Molecules and Chelators Used for the Control of Essential and Toxic Metals in Health and Disease: From Molecular Interactions to Clinical Effects and Applications (Guest Editor: George J. Kontoghiorghes)]

G. Kontoghiorghes, 2005 .

Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications

G. Kontoghiorghes, 2023, International journal of molecular sciences.

Metal Complexes of Omadine (N-Hydroxypyridine-2-thione): Differences of Antioxidant and Pro-Oxidant Behavior in Light and Dark Conditions with Possible Toxicity Implications

G. Kontoghiorghes, N. Polyakov, O. Selyutina, 2023, Molecules.

Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology

G. Kontoghiorghes, 2022 .

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

G. Kontoghiorghes, N. Andreou, C. Kontoghiorghe, 2014, World journal of methodology.

The Proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies

G. Kontoghiorghes, 2013, Toxicology mechanisms and methods.

Iron mobilization using chelation and phlebotomy.

J. Aaseth, T. Flaten, G. Kontoghiorghes, 2012, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

G. Kontoghiorghes, 2023, International journal of molecular sciences.

A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response.

G. Kontoghiorghes, 2013, Expert opinion on drug safety.

Post COVID-19 Reflections and Questions: How Prepared Are We for the Next Pandemic?

G. Kontoghiorghes, C. Kontoghiorghe, A. Kolnagou, 2024, International journal of molecular sciences.

The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

G. Kontoghiorghes, 2024, International journal of molecular sciences.

The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites

G. Kontoghiorghes, 2024, International journal of molecular sciences.

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

G. Kontoghiorghes, Savvas N. Georgiades, Ioannis Ioannidis, 2024, International Journal of Molecular Sciences.

The Effects of Bicarbonate and its Combination with Chelating Agents Used for the Removal of Depleted Uranium in Rats

Yuyuan Xie, A. Katoh, G. Kontoghiorghes, 2008, Hemoglobin.